These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31522830)

  • 1. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
    Zak M; Dengler HS; Rajapaksa NS
    Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Inhaled Pan-JAK Inhibitor, LAS194046, Reduces Allergen-Induced Airway Inflammation, Late Asthmatic Response, and pSTAT Activation in Brown Norway Rats.
    Calbet M; Ramis I; Calama E; Carreño C; Paris S; Maldonado M; Orellana A; Calaf E; Pauta M; De Alba J; Bach J; Miralpeix M
    J Pharmacol Exp Ther; 2019 Aug; 370(2):137-147. PubMed ID: 31085698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK inhibitors for asthma.
    Georas SN; Donohue P; Connolly M; Wechsler ME
    J Allergy Clin Immunol; 2021 Oct; 148(4):953-963. PubMed ID: 34625142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases.
    Bach J; Eastwood P; González J; Gómez E; Alonso JA; Fonquerna S; Lozoya E; Orellana A; Maldonado M; Calaf E; Albertí J; Pérez J; Andrés A; Prats N; Carreño C; Calama E; De Alba J; Calbet M; Miralpeix M; Ramis I
    J Med Chem; 2019 Oct; 62(20):9045-9060. PubMed ID: 31609613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
    Hosseini A; Gharibi T; Marofi F; Javadian M; Babaloo Z; Baradaran B
    J Cell Physiol; 2020 Sep; 235(9):5903-5924. PubMed ID: 32072644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of JAK inhibitors for the treatment of immune-mediated diseases: kinase-targeted inhibitors and pseudokinase-targeted inhibitors.
    Kim HO
    Arch Pharm Res; 2020 Nov; 43(11):1173-1186. PubMed ID: 33161563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
    Howell MD; Kuo FI; Smith PA
    Front Immunol; 2019; 10():2342. PubMed ID: 31649667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients.
    Southworth T; Plumb J; Gupta V; Pearson J; Ramis I; Lehner MD; Miralpeix M; Singh D
    Respir Res; 2016 Oct; 17(1):124. PubMed ID: 27716212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
    El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
    Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
    Kotyla PJ; Islam MA; Engelmann M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
    T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
    BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus kinase inhibitors in autoimmune diseases.
    O'Shea JJ; Kontzias A; Yamaoka K; Tanaka Y; Laurence A
    Ann Rheum Dis; 2013 Apr; 72 Suppl 2(0 2):ii111-5. PubMed ID: 23532440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting JAK-STAT signal transduction in IBD.
    Soendergaard C; Bergenheim FH; Bjerrum JT; Nielsen OH
    Pharmacol Ther; 2018 Dec; 192():100-111. PubMed ID: 30048708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK Inhibitors in Cytokine Storm Syndromes.
    Keenan C; Albeituni S; Nichols KE; Hines M
    Adv Exp Med Biol; 2024; 1448():583-600. PubMed ID: 39117841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinases to jakinibs: from basic insights to clinical practice.
    Gadina M; Le MT; Schwartz DM; Silvennoinen O; Nakayamada S; Yamaoka K; O'Shea JJ
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i4-i16. PubMed ID: 30806710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders.
    Kalantari Y; Sadeghi S; Asadi D; Goodarzi A
    Int Immunopharmacol; 2022 Sep; 110():108923. PubMed ID: 35717838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Janus Kinase (JAK) Inhibitor in Autoimmune Ocular Inflammation: A Systematic Review.
    Wen J; Hu H; Chen M; Yang H; Zhao Y; Liu Y
    J Immunol Res; 2021; 2021():2324400. PubMed ID: 34966823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
    Kotyla PJ; Engelmann M; Giemza-Stokłosa J; Wnuk B; Islam MA
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
    Roskoski R
    Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.